Laurence Reid Joins KalVista Board, Bringing 30 Years Of Biotech Leadership
Laurence Reid, Ph.D., appointed to KalVista Pharmaceuticals Board of Directors, bringing over 30 years of biotech leadership.
Breaking News
Nov 27, 2024
Simantini Singh Deo
KalVista Pharmaceuticals, Inc. announced the appointment of Laurence Reid, Ph.D., to its Board of Directors, effective immediately. Dr. Reid brings over 30 years of industry expertise and is recognized for his leadership and contributions to company growth and innovation.
Ben Palleiko, Chief Executive Officer of KalVista, said in a statement, “I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors. His extensive biopharmaceutical and strategic experience will be a tremendous asset as the Company continues to progress sebetralstat towards global market approval and commercialization.”
“I am excited to join the KalVista Board at this transformational time in the Company’s journey. I believe sebetralstat has the potential to significantly improve the lives of people living with hereditary angioedema. I look forward to working with the team on the Company’s transition to a commercial organization and supporting its long-term growth,” stated Dr. Laurence Reid.
Dr. Reid previously served as CEO of Decibel Therapeutics, overseeing its operations until its acquisition by Regeneron Pharmaceuticals in September 2023. Earlier in his career, he was an entrepreneur in residence at Third Rock Ventures, focusing on pioneering drug discovery projects. He also held the position of CEO at Warp Drive Bio, a company dedicated to oncology and antibiotic drug discovery, guiding it through its 2018 merger with Revolution Medicines.
Additionally, Dr. Reid served as Chief Business Officer at Alnylam Pharmaceuticals and Ensemble Therapeutics and held senior leadership roles at Millennium Pharmaceuticals.
Currently, Dr. Reid chairs the board of Broken String Biosciences, serves on the boards of Garuda Therapeutics and The Possible Zone, and is an advisor to Life Science Cares and Mount Auburn Hospital. His extensive experience in biotech leadership and strategic business development will be instrumental to KalVista’s future endeavours.